TheEdgeResearch
Home / Stocks / CLLKF

BICO Group AB (publ) (CLLKF)

OTC Healthcare Medical - Devices
$1.47 ▼ -42.14%
Market Cap
$101.6M
Sector
Healthcare
Industry
Medical - Devices
Beta
2.56
52-Wk Range
1.47-2.5425
CEO
Anders Fogelberg
Country
SE
Currency
USD

BICO Group AB (publ) operates in the Medical - Devices industry of the Healthcare sector, headquartered in Gothenburg, VG, SE. The stock last traded at $1.47, down 42.14% on the session, giving a market capitalisation of $101.6M. On trailing twelve-month figures it carries a trailing P/E of -2.39, a net margin of -28.3%. Its beta of 2.56 implies it has historically moved more than the broad market.

Valuation & profitability (TTM)
P/E
-2.39
Price / Sales
0.66
Price / Book
0.80
EV / EBITDA
11.35
Gross margin
52.1%
Operating margin
-5.0%
Net margin
-28.3%
Return on equity
—
Debt / equity
0.52
Current ratio
2.46
Dividend yield
0.0%
Payout ratio
0.0%
Company profile
Exchange
Other OTC
Employees
695
IPO date
2017-11-15
Headquarters
Gothenburg, VG, SE
About BICO Group AB (publ)

BICO Group AB (publ) is a global bio-convergence enterprise, extending its operations across North America, Europe, Asia, and other international markets. Its business is segmented into two primary divisions: Laboratory Solutions and Bioautomation. The Laboratory Solutions division equips researchers with advanced tools like 3D bioprinters, hybrid microscopes, and instruments for single-cell dispensing and liquid handling. It also supplies essential consumables such as bioinks, reagents, microscope lenses, and specialized software, alongside 3D reconstructed human tissues crucial for regulatory testing. Furthermore, this segment provides specialized services in 3D cell culture, tissue imaging, multiplex imaging, and digital pathology, primarily benefiting pharmaceutical and biotechnology firms. Conversely, the Bioautomation segment caters to industrial clients with precision dispensing and biosensor technologies, while also delivering diagnostic automation and sophisticated robotics solutions to the medical and diagnostics sectors. Beyond these segments, BICO Group's comprehensive portfolio includes solutions for tissue engineering, multi-omics, cell line development, and diagnostics, contributing to a robust industrial ecosystem. Its principal clientele spans the medical, pharmaceutical, and cosmetic industries. Originally established in 2016 as Cellink AB (publ), the company adopted its current name, BICO Group AB (publ), in August 2021. Its headquarters are located in Gothenburg, Sweden.

Comparable companies

BICO Group AB (publ) is most often compared with the following Healthcare names:

BRIBFCYBQFCYBQYMLLCFNDTPNGENFPXMBFVMTHFWLDFFYOURF
More research on CLLKF
CLLKF technical analysis CLLKF TheEdge Score Compare against peers
Open full interactive analysis & DCF →